DC101 treatment increased mural cell coverage of tumor vessels, which could render the endothelium resistant to anti-angiogenic treatment
DC101 treatment increased mural cell coverage of tumor vessels, which could render the endothelium resistant to anti-angiogenic treatment. without affecting vessel regression and compromised the survival benefit of VEGFR2 inhibition by increasing vascular permeability. VEGFR2 inhibition normalized tumor vasculature while ectopic expression of Ang-2 diminished the beneficial effects of VEGFR2 blockade by inhibiting vessel normalization.…